Efficacy and tolerability of a novel herbal formulation for weight management

Obesity

Volumn 21, Issue 5, 2013, Pages 921-927

  Stern, J S ^a,b   Peerson, J ^a   Mishra, A T ^c   Sadasiva Rao, M V ^d   Rajeswari, K P ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Radiodiagnosis   (India)

^d Alluri Sitaramaraju Academy of Medical Sciences   (India)

^e Suraksha Health Village   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPOPHILIN; ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CD36 ANTIGEN; CHOLESTEROL; FAT DROPLET; FATTY ACID; GARCINIA MANGOSTANA EXTRACT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PLANT EXTRACT; SPHAERANTHUS INDICUS EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANKLE PAIN; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTERACEAE; BACKACHE; BODY MASS; BODY WEIGHT; CANCER CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EMBRYO; ENCAPSULATION; FATTY ACID TRANSPORT; FEMALE; GARCINIA MANGOSTANA; GASTROINTESTINAL IRRITATION; HEART FUNCTION; HUMAN; IN VITRO STUDY; LEG PAIN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NAUSEA; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SPHAERANTHUS INDICUS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION;

3T3-L1 CELLS; ADIPONECTIN; ADULT; ANIMALS; ANTI-OBESITY AGENTS; ASTERACEAE; BODY MASS INDEX; CARRIER PROTEINS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; GARCINIA MANGOSTANA; HUMANS; MALE; MEMBRANES; MICE; OBESITY; PHOSPHOPROTEINS; PHYTOTHERAPY; PLANT EXTRACTS; PPAR GAMMA; TREATMENT OUTCOME; WEIGHT LOSS;

GARCINIA MANGOSTANA; SPHAERANTHUS INDICUS;

EID: 84879398041     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20211     Document Type: Article

References (32)

1. Faust IM, Johnson PR, Stern JS, Hirsch J,. Diet-induced adipocytes number increase in adult rats: a new model of obesity. Am J Physiol 1978; 235: E279-E286.
2. Klyde BJ, Hirsch J,. Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J Lipid Res 1979; 20: 705-715.
3. Klyde BJ, Hirsch J,. Isotopic labeling of DNA in rat adipose tissue: evidence for proliferating cells associated with mature adipocytes. J Lipid Res 1979; 20: 691-704.
4. World Health Organization (WHO). Obesity and overweight. Fact sheet N°311. March, 2011.
5. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303235-303241.
6. Nguyen DM, El-Serag HB,. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.
7. Mallare JT, Karabell AH, Velasquez-Mieyer P, Stender SRS, Christensen ML,. Current and future treatment of metabolic syndrome and type 2 diabetes in children and adolescents. Diabetes Spectrum 2005; 18: 220-228.
8. Daniels S,. Pharmacological treatment of obesity in pediatric patients. Pediatr Drugs 2001; 3: 405-410.
9. Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention and treatment. Circulation 2005; 111: 1999-2012.
10. Rucker D, Padwal R, Li SK, Curioni C, Lau DC,. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
11. Giri M,. Medical management of obesity. Acta Clin Belg 2006; 61: 286-294.
12. Perumal Samy R, Natesan Pushparaj P, Gopalakrishnakone P,. A compilation of bioactive compounds from Ayurveda. Bioinformation 2008; 3: 100-110.
13. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
14. Sengupta K, Banerjee S, Saxena NK, Banerjee SK,. Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression suppressed by estradiol. Mol Cancer Res 2004; 2: 150-158.
15. Ukkola O, Santaniemi M,. Adiponectin: a link between excess adiposity and associated comorbidities. J Mol Med 2002; 80: 696-702.
16. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2008; 288: 1102-1107.
17. Hong JW, Park KW,. Further understanding of fat biology: lessons from a fat fly. Exp Mol Med 2010; 42: 12-20.
18. Bickel PE, Tansey JT, Welte MA,. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 2009; 1791: 419-440.
19. Febbraio M, Silverstein RL,. CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 2007; 39: 2012-2030.
20. Stern JS, Hirsch J, Blair SN, et al. Weighing the options: criteria for evaluating weight management programs. The committee to develop criteria for evaluating the outcomes of approaches to prevent and treat obesity. Obes Res 1995; 3: 591-604.
21. Brun RP, Spiegelman BM,. PPARγ and the molecular control of adipogenesis. J Endocrinol 1997; 155: 217-218.
22. Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001; 108: 1001-1003.
23. Jones JR, Barrick C, Kim KA, et al. Deletion of PPARγ in adipose tissue of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 2005; 102: 6207-6212.
24. Bonen A, Tandon NN, Glatz JFC, Luiken JJFP, Heigenhauser GJF,. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obesity 2006; 30: 877-883.
25. Faleck DM, Ali K, Roat R, et al. Adipose differentiation-related protein regulates lipids and insulin in pancreatic islets. Am J Physiol Endocrinol Metab 2010; 299: E249-E257.
26. Tansey JT, Sztalryd C, Gruia-Gray J, et al. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 2001; 98: 6494-6499.
27. Aprahamian TR, Sam F,. Adiponectin in cardiovascular inflammation and obesity. Int J Inflam 2011; 376909: 1-8.
28. Berg AH, Scherer PE,. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
29. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
30. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888.
31. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
32. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.